Skip to search formSkip to main contentSkip to account menu

Melanoma TRP2 CTL Epitope Vaccine SCIB1

Known as: SCIB1 
A proprietary DNA-based cancer vaccine that encodes a melanoma antigen tyrosinase-related protein 2 (TRP2) cytotoxic T-lymphocyte (CTL) epitope and a… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
A clinical trial of a DNA vaccine (SCIB1) that targets dendritic cells in vivo in fully resected melanoma patients; a vaccine to prevent disease recurrence?
Background: SCIB1 is a DNA vaccine encoding a human IgG1 antibody with CDRs that contain four epitopes from two melanoma… 
2014
2014
Phase I trial of ImmunoBody in melanoma patients.
ImmunoBody is a DNA vaccine encoding a human IgG1 antibody with T cell epitopes grafted into its CDR regions. SCIB1 has 3… 
2014
2014
Abstract CT331: Phase I/II trial of a novel antibody DNA immunotherapy, targeting CD64, in the treatment of Melanoma
SCIB1 is a novel DNA immunotherapy that has epitopes from gp100 and TRP-2 melanoma antigens, engineered into a human IgG1… 
2013
2013
Priming of Autoreactive CD8+ T Cells Is Inhibited by Immunogenic Peptides Which Are Competitive for Major Histocompatibility Complex Class I Binding
In the present study, we investigated if priming of autoreactive CD8+ T cells would be inhibited by competitive peptides for… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)